A comparison of immediate with deferred zidovudine therapy for asymptomatic hiv-infected adults with cd4 cell counts of 500 or more per cubic millimeter

Paul A. Volberding, Stephen W. Lagakos, Janet M. Grimes, Daniel S. Stein, James Rooney, Tze Chiang Meng, Margaret A. Fischl, Ann C. Collier, John P. Phair, Martin S. Hirsch, W. David Hardy, Henry H. Balfour, Richard C. Reichman

Research output: Contribution to journalArticlepeer-review

111 Scopus citations


The clinical benefits of zidovudine remain unproved in patients with asymptomatic human immunodeficiency virus (HIV) infection when CD4 cell counts exceed 500 per cubic millimeter. We compared zidovudine therapy given immediately with deferred therapy in such subjects. Beginning in 1987, subjects with asymptomatic HIV infection and 500 or more CD4 cells per cubic millimeter were randomly assigned to receive placebo or zidovudine (either 500 or 1500 mg per day, starting immediately). In 1989, the study was modified so that open-label treatment with 500 mg of zidovudine per day (deferred therapy) was offered when CD4 cell counts fell below 500 per cubic millimeter. The study end points included overall survival, survival free of the acquired immunodeficiency syndrome (AIDS), toxic effects, and changes in CD4 cell counts. There were 1637 subjects who could be evaluated: 547 in the deferred-therapy group, 549 in the group receiving 500 mg of zidovudine immediately, and 541 in the 1500-mg group. The subjects were followed for up to 6.5 years (group medians, 4.8, 4.8, and 4.9, respectively). There was no significant difference in AIDS-free survival in the deferred-therapy group as compared with the low-dose or high-dose groups (81 cases of progression to AIDS or death vs. 81 and 74, respectively; P = 0.95 and P = 0.13) or in overall survival (51 deaths vs. 47 and 46; P = 0.25 and P = 0.16). The decline in CD4 cells was slower in both immediate-therapy groups than in the deferred-therapy group (P<0.001 for both). Adverse effects were uncommon, and before the study modification their incidence was similar among the treatment groups, but severe anemia and granulocytopenia were more frequent in the 1500-mg group than in the deferred-therapy group (P<0.001). In asymptomatic, HIV-infected adults with 500 or more CD4 cells per cubic millimeter, treatment with zidovudine slows the decline in the CD4 cell count but does not significantly prolong either AIDS-free or overall survival. These results do not encourage the routine use of zidovudine monotherapy in this population. Zidovudine monotherapy is an effective treatment for symptomatic human immunodeficiency virus (HIV) disease, but its use in persons with asymptomatic infection remains controversial. Zidovudine therapy has been associated with a slowing in the clinical progression of disease and with longer survival in patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex.1In patients with mildly symptomatic HIV disease, zidovudine slowed the rate of progression to more severe stages of disease.2,3In 1990, the drug was shown to slow the clinical progression to AIDS substantially in persons with asymptomatic HIV infection and fewer than 500 cD4 cells per cubic. . .

Original languageEnglish (US)
Pages (from-to)401-407
Number of pages7
JournalNew England Journal of Medicine
Issue number7
StatePublished - Aug 17 1995

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'A comparison of immediate with deferred zidovudine therapy for asymptomatic hiv-infected adults with cd4 cell counts of 500 or more per cubic millimeter'. Together they form a unique fingerprint.

Cite this